R&D channel feed

Anap­tys­Bio de­scribes ‘JAK-like’ ef­fi­ca­cy for PD-1 drug in rheuma­toid arthri­tis

Last month

Sion­na se­lects which cys­tic fi­bro­sis drug it will study in a mid-stage test

Last month

Lil­ly makes a move for long-act­ing in­cretins in tech deal with Swedish biotech

Last month
Deals

BioN­Tech presents im­pres­sive ear­ly da­ta for PD-L1xVEGF in mesothe­lioma

Last month
Deals

At AS­CO, cell ther­a­pies for dead­ly form of brain can­cer make ear­ly strides

Last month
Cell/Gene Tx

Lyra’s stock soars on Phase 3 suc­cess for chron­ic rhi­nos­i­nusi­tis treat­ment

Last month

Re­gen­eron makes $80M obe­si­ty deal with Han­soh

Last month
Deals
China

Phase 3 or bust: Why Lil­ly won't run mid-stage can­cer tri­als

Last month

En­her­tu com­bo has the mak­ings of a new stan­dard in HER2-pos­i­tive breast can­cer

Last month
Pharma

Sanofi to snap up Blue­print Med­i­cines and mas­to­cy­to­sis drug Ay­vak­it for $9.1B

Last month
Deals

Kymera un­veils ‘ex­cep­tion­al’ Phase 1 da­ta for its Dupix­ent-in-a-pill pro­gram

Last month

Ve­ra posts pos­i­tive Phase 3 rare kid­ney dis­ease da­ta, but crowd­ed mar­ket looms

Last month
Pharma

In race with Merus, Bicara makes the case for two-year sur­vival da­ta

Last month

As­traZeneca de­tails its oral SERD 'switch­ing' reg­i­men as fea­si­bil­i­ty ques­tions re­main

Last month

As life-sav­ing check­point drugs move to ear­li­er can­cers, re­searchers de­bate how best to use them

Last month

Take­da, Pro­tag­o­nist un­veil ple­nary da­ta for po­ten­tial block­buster rare blood dis­ease drug

Last month

Im­mat­ics re­ports more ear­ly-stage da­ta for melanoma cell ther­a­py with piv­otal tri­al un­der­way

Last month
Cell/Gene Tx

En­her­tu ex­tends life by three months for some stom­ach can­cer pa­tients, study finds

Last month
Pharma

Gilead, Mer­ck re­veal 'prac­tice-chang­ing' da­ta for Trodelvy-Keytru­da com­bo in ag­gres­sive breast can­cer

Last month
Pharma

Arv­inas, Pfiz­er's PRO­TAC in breast can­cer no bet­ter than oral SERDs

Last month

Sum­mit’s dis­ap­point­ing sur­vival read­out rais­es stakes for full da­ta

Last month

Q&A: Why for­mer Sen. Kyrsten Sine­ma is back­ing a psy­che­del­ic med­i­cine with po­ten­tial­ly more up­side, but more risk

Last month
People

Pfiz­er's Braftovi com­bo dou­bles sur­vival time for some col­orec­tal can­cer pa­tients

Last month
Pharma

Sanofi, Re­gen­eron re­port un­der­whelm­ing COPD da­ta for IL-33 an­ti­body, shares drop

Last month
First page Previous page 2345678 Next page Last page
A service from the Financial Times